(Australia-NewsWire.Com, August 11, 2017 ) The Global Nuclear medicine Radiopharmaceuticals market is estimated at $4.5billion in 2015 and is expected to reach $8.44billion by 2020, growing at a CAGR of 13.4%. Nuclear medicine falls under the field of Molecular imaging, which involves usage of minute amount of radioactive material (radiopharmaceuticals) to diagnose and treat disease. View Full Report @ http://www.marketdataforecast.com/market-reports/global-nuclear-medicine-radiopharmaceuticals-market-130/ Increasing incidence of cancer and cardiac ailments, immense technological advancements, increasing demand for SPECT and PET applications along with the growing public awareness for healthcare are fuelling the market growth for Radiopharmaceuticals.Further, Integration of X ray tomography (CT) into SPECT has recently emerged as a excellent diagnostic tool in medical imaging and is considered to be a driving factor for the growth of the market. Strict regulatory framework which pose as a hurdle to translational research and clinical investigations and reimbursement issues are blocking the growth of the market. In addition, shorter half-life of radiopharmaceuticals and competition from orthodox diagnostic procedures are also restraining the global nuclear medicine Radioisotopes market. Download Free Sample Report @ http://www.marketdataforecast.com/market-reports/global-nuclear-medicine-radiopharmaceuticals-market-130/request-sample Market Segmentation • By Type o Diagnostic Radioisotopes o SPECT Technetium-99m Thallium-201 Gallium-67 Iodine-23 Others o PET Fluorine-18 Rubidium-82 Others • Therapeutic Radioisotopes o Beta Emitters Iodine-131 Yttrium-90 Samarium-153 Rhenium-186 Lutetium-177 Alpha Emitters • Radium-223 o Brachytherapy o Cesium-131 o Iodine-125 o Palladium-103 o Iridium-192 • By Application o Cardiology o Lymphoma o Thyroid o Neurology o Oncology o Others
Avail Discount @ http://www.marketdataforecast.com/market-reports/global-nuclear-medicine-radiopharmaceuticals-market-130/request-discount Based on market share estimation 90 % of the radiopharmaceuticals market is dominated by diagnostic radioisotopes while therapeutic radioisotopes contribute 10% of the market. The F-18 market is mostly contributed by F-18 FDG tracers though this market is enriched with future tracers such as F-18 Florbetapir and F-18 Choline. The promising clinical outcome of these tracers has gained the business interest of major research institutes and PET isotope players. Ga-68 and Rb-82 are two other potential isotopes in the PET diagnostic market, ensuring high growth of the diagnostics segment. Diagnosis of coronary artery disease, bone metastasis, and Alzheimer’s disease are the most promising indications for the future PET radioisotopes market.
The Global Nuclear medicine Radiopharmaceuticals market study offers the following deliverables: • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the geographical areas in which this industry is blooming • Segment-level analysis on basis of type, application, end-user along with market size forecasts and y-o-y estimations to detect key areas of industry growth in detail • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics • Study of macro and micro environmental factors that effect the global market presented in an extensive strategic analyses section containing PESTLE and Porter’s Five Forces Analyses • A comprehensive listing of key market players along with company overview, product portfolios, key financial information (subjected to availability), SWOT analysis and analyst overview to study and sustain the market environment • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies • Expertly devised Market Outlook along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market North America is the dominant market for diagnostic radioisotopes. Within North America, US is the largest consumer market for radioisotopes and Canada is the largest producer of Tc-99m. India and China hold a potential market for radioisotope due to rising healthcare and increasing demand for different radioisotopes in various treatments and applications. Buy now @ https://www.marketdataforecast.com/cart/buy-now/global-nuclear-medicine-radiopharmaceuticals-market-130 Some of the key players influencing the global nuclear medicine market are GE Healthcare, Hologic Inc., Medix Inc., SegamiCorporation,PositronCorporation,Bracco Imaging S.p.A, Naviscan Inc., Bayer Healthcare, Lantheus Medical Imaging, Inc. and IBA Molecular Imaging. About Market Data Forecast: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more info kindly visit, www.marketdataforecast.com
Contact: Abhishek Shukla Sales Manager (International Business Development) Market Data Forecast Direct Line: +1-888-702-9626 Mobile: +91 998 555 0206 Mail: abhishek@marketdataforecast.com